A vaccine against the biggest bacterial killer on the planet is a step closer to being available with funding secured for preclinical trials.
Professor James Paton, Director of the University of Adelaide’s Research Centre for Infectious Diseases and his team have been working on a vaccine for Streptococcus pneumoniae (the pneumococcus) that could save two million lives globally a year and address the overuse of antibiotics that leads to resistance.
“The pneumococcus is the biggest bacterial killer on the planet. It’s the most common cause of pneumonia, which is responsible for about 20 per cent of deaths from all causes in children under 5 years in developing countries. Globally, the pneumococcus accounts for about two million deaths a year,” says Professor Paton.
Streptococcus pneumoniae, which is principally spread through close contact with infected but asymptomatic carriers, is the leading cause of sinus and ear infections, meningitis, sepsis and pneumonia. Ear infections are one of the most common childhood illnesses that are habitually treated with antibiotics, contributing to increasing bacterial resistance.
“Vaccinating people against Streptococcus pneumoniae would help to ameliorate the global challenge of increasing bacterial resistance to antibiotics,” says Professor Paton.
“The problem with the existing pneumococcal vaccine is that it targets the outside coat of complex carbohydrates – of which there are 98 structurally distinct types. The current vaccine costs about $150 a dose and only covers 13 types.
“What we have done is to remove this coat to expose all the surface proteins that are common to all pneumococcal types. The body mounts an immune response to these surface proteins if previously exposed or vaccinated.”
Sixteen months ago, Adelaide-based GPN Vaccines Pty Ltd was created to develop this novel “whole bacterial” vaccine (Gamma-PNTM) against Streptococcus pneumoniae. The company has already secured investment from local angel investors as well as a major grant from the National Health & Medical Research Council and a Commercialisation grant from the South Australian Government.
GPN Vaccines has now raised a further AUS$1.1 million from international and Australian-based investors that will be used for preclinical evaluation of the Gamma-PNTM vaccine. Toxicity tests will be carried out as well as the scale-up clinical grade manufacture of the vaccine in readiness for testing in a first-in-human clinical trial.
Learn more: STEP FORWARD FOR PNEUMONIA VACCINE DEVELOPMENT
The Latest on: Pneumonia
via Google News
The Latest on: Pneumonia
- PCV10 vaccine against pneumonia sharply reduces incidence of serious pneumococcal disease on April 16, 2019 at 11:43 pm
A vaccine against Streptococcus pneumoniae, a major cause of childhood illness and mortality in the developing world, sharply reduced the incidence of serious pneumococcal disease among children in a ... […]
- Whoopi Goldberg Reveals She Was Hospitalized Again Following Pneumonia Scare on April 16, 2019 at 12:54 am
Whoopi Goldberg was back in the hospital. Less than a month after the 63-year-old co-host returned to The View after suffering from pneumonia and sepsis, Goldberg revealed on Monday's episode of the ... […]
- AEDs tied to higher pneumonia risk in Alzheimer patients on April 15, 2019 at 2:56 pm
(HealthDay)—Antiepileptic drug (AED) use may increase the risk for pneumonia in patients with Alzheimer disease (AD), according to a study recently published in the Journal of Alzheimer's Disease. […]
- Pfizer's 20-valent pneumonia vaccine candidate shows positive action in mid-stage study on April 15, 2019 at 4:56 am
Results from a Phase 2 clinical trial evaluating Pfizer's (NYSE:PFE) PF-06482077, a 20-valent pneumococcal conjugate vaccine, in 444 adults showed robust immunogenicity. The data were presented at ... […]
- Merck's Zerbaxa on par with meropenem in late-stage pneumonia study on April 15, 2019 at 4:08 am
A Phase 3 clinical trial, ASPECT-NP, evaluating Merck's (NYSE:MRK) combo antibiotic ZERBAXA (ceftolozane and tazobactam) in adult patients with ventilated nosocomial (hospital acquired) pneumonia ... […]
- Wandering Ridgewood Goat Recovering From Pneumonia At Oradell Animal Hospital on April 13, 2019 at 8:55 am
PARAMUS - A young goat found wandering a Ridgewood cemetery last week is continuing to recuperate at Oradell Animal Hospital. After being corralled by police, cemetery workers and animal control on ... […]
- Greece: MSF uses ‘Humanitarian Mechanism’ for first time in Europe due to high price of pneumonia vaccine on April 12, 2019 at 5:19 am
Medical humanitarian organisation uses programme to access affordable versions of pneumonia vaccine to protect refugee children in Greece against the number one childhood killer worldwide Athens ... […]
- Legislator Chalks Medical Emergency up to Pneumonia on April 11, 2019 at 1:40 pm
OLYMPIA, Wash. (AP) — A Washington state legislator has returned to work the day after emergency medical personnel were summoned to the Capitol. He chalked the episode up to pneumonia. In a statement, ... […]
- Advisers: Baltimore’s mayor still recovering from pneumonia on April 10, 2019 at 8:45 am
BALTIMORE — Close advisers to Baltimore’s embattled mayor said Tuesday that she’s staying out of public view because of a serious case of pneumonia, not the mounting scandal involving her sale of her ... […]
- Pugh Still Recovering From Pneumonia on April 10, 2019 at 8:28 am
BALTIMORE (AP) — Close advisers to embattled Baltimore Mayor Catherine Pugh say she's still recovering from a serious case of pneumonia. The Baltimore Sun reported Tuesday that Catherine Pugh ... […]
via Bing News